Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
11 Pt 1
|
| pubmed:dateCreated |
1978-12-20
|
| pubmed:abstractText |
The compound 4'-(9-acridinylamino)methanesulfon-m-anisidide is a new derivative that was evaluated in a Phase 1 clinical trial. The schedule of drug administration consisted of daily i.v. injection for 3 consecutive days, repeated at 3-week intervals. Twenty-six patients received a total of 63 courses of 4'-(9-acridinylamino)methanesulfon-m-anisidide in a dose range from 4 to 50 mg/sq m/day. Hematopoietic toxicity was dose limiting, but it was of short duration and rapidly reversible. Mild nausea and vomiting were observed in 16% of the courses, and a mild degree of phlebitis was observed in 10% of the courses. Responses were observed in two patients with adenocarcinoma of the lung and one each of melanoma and acute myeloblastic leukemia. Phase 2 studies of 4'-(9-acridinylamino)methanesulfon-m-anisidide are planned at a starting dose of 40 mg/sq m/day for 3 days in good-risk patients and at 25 to 30 mg/sq m/day for 3 days in poor-risk patients. Course of treatment would be repeated at 21-day intervals.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0008-5472
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
38
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
3712-6
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:279397-Acridines,
pubmed-meshheading:279397-Adenocarcinoma,
pubmed-meshheading:279397-Adult,
pubmed-meshheading:279397-Aged,
pubmed-meshheading:279397-Antineoplastic Agents,
pubmed-meshheading:279397-Bone Marrow,
pubmed-meshheading:279397-Drug Administration Schedule,
pubmed-meshheading:279397-Drug Evaluation,
pubmed-meshheading:279397-Female,
pubmed-meshheading:279397-Humans,
pubmed-meshheading:279397-Injections, Intravenous,
pubmed-meshheading:279397-Leukemia, Myeloid, Acute,
pubmed-meshheading:279397-Lung Neoplasms,
pubmed-meshheading:279397-Male,
pubmed-meshheading:279397-Melanoma,
pubmed-meshheading:279397-Middle Aged,
pubmed-meshheading:279397-Neoplasms,
pubmed-meshheading:279397-Phenylenediamines,
pubmed-meshheading:279397-Remission, Spontaneous
|
| pubmed:year |
1978
|
| pubmed:articleTitle |
Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|